Literature DB >> 6576908

Dissociation of the spasmolytic and metabolic effects of glucagon.

K Damm Jørgensen, J U Weis, B Diamant.   

Abstract

Glucagon and glucagon-(1-21)-peptide were equipotent with regard to inhibitory effect on the amplitude of electrically evoked contractions of the isolated guinea-pig ileum. The effect was not potentiated by isobutylmethylxanthine (IBMX) nor inhibited by phentolamine or propranolol. Both peptides inhibited intestinal motility in rabbits in vivo. Glucagon and equimolar doses of glucagon-(1-21)-peptide exerted a relaxing effect on the rabbit gall bladder in vitro and in vivo and increased bile flow in rats. Both peptides inhibited pentagastrin stimulated gastric acid secretion in cats. However, contrary to glucagon, glucagon-(1-21)-peptide did not increase blood glucose and plasma IRI levels after intravenous administration to rats in vivo. Whereas the entire glucagon molecule was required for the metabolic effects, the amino acid sequence (1-21) of glucagon exerted a full spasmolytic action on the enteric muscles and the biliary tree. The spasmolytic effects on these organs are therefore likely to be mediated via a mechanism that does not involve the activation of adenyl cyclase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6576908     DOI: 10.1016/0014-2999(83)90552-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Effect of intravenous glucagon and glucagon-(1-21)-peptide on motor activity of sphincter of Oddi in humans.

Authors:  J Ponce; V Garrigues; V Pertejo; T Sala; M J Lazaro; A De Val; J Picazo
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

2.  Glucagon-(1-21)-peptide. Study of its action on sphincter of Oddi function by endoscopic manometry.

Authors:  J F Rey; M Greff; J Picazo
Journal:  Dig Dis Sci       Date:  1986-04       Impact factor: 3.199

Review 3.  Antispasmodic drugs in colonoscopy: a review of their pharmacology, safety and efficacy in improving polyp detection and related outcomes.

Authors:  Santosh Sanagapalli; Kriti Agnihotri; Rupert Leong; Crispin John Corte
Journal:  Therap Adv Gastroenterol       Date:  2016-10-03       Impact factor: 4.409

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.